Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest

被引：1
|
作者：
Reich, Kristian [1 ]
Simpson, Eric [2 ]
Langley, Richard [3 ]
Warren, Richard B. [4 ,5 ]
Costanzo, Antonio [6 ,7 ]
Saeki, Hidehisa [8 ]
Almgren, Peter [9 ]
Gjerum, Le [9 ]
Carlsson, Anna [9 ]
Gooderham, Melinda [10 ,11 ,12 ]
Pinter, Andreas [13 ]
Weller, Marjolein De Bruin [14 ]
Blauvelt, Andrew [15 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany
[2] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA
[3] Dalhousie Univ, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada
[4] Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester, England
[5] Univ Manchester, NIHR Biomed Res Ctr, Manchester, Lancs, England
[6] Humanitas Univ, Dept Biomed Sci, Dermatol Unit, Milan, Italy
[7] IRCSS Humanitas Res Hosp, Skin Pathol Lab, Milan, Italy
[8] Nippon Med Sch, Dept Dermatol, Tokyo, Japan
[9] LEO Pharm AS, Ballerup, Denmark
[10] SKiN Ctr Dermatol, Peterborough, ON, Canada
[11] Queens Univ, Dept Dermatol, Kingston, ON, Canada
[12] Prob Med Res, Waterloo, ON, Canada
[13] Goethe Univ Frankfurt Main, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
[14] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands
[15] Oregon Med Res Ctr, Portland, OR USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
moderate-to-severe; tralokinumab; safety; adverse events;
D O I：
10.1093/bjd/ljac140.009
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
309
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
    Awosika, Olabola
    Kim, Lori
    Mazhar, Momina
    Rengifo-Pardo, Monica
    Ehrlich, Alison
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2018, 11 : 41 - 49
  • [22] EFFICACY AND SAFETY OF DUPILUMAB TREATMENT UP TO 1 YEAR IN INFANTS AND PRESCHOOL CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Cork, Michael J.
    Paller, Amy S.
    Siegfried, Elaine C.
    Xiao, Jing
    Prescilla, Randy
    Dubost-Brama, Ariane
    Bansal, Ashish
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 53
  • [23] EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Worrell, Richard
    Paller, Amy S.
    Siegfried, Elaine C.
    Simpson, Eric L.
    Wollenberg, Andreas
    Gonzalez, Mercedes E.
    Sidbury, Robert
    Lockshin, Benjamin
    Dubost-Brama, Ariane
    Bansal, Ashish
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 31 - 32
  • [24] Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Torres, Tiago
    Petersen, Anne Sohrt
    Ivens, Ulla
    Vilaro, Albert Bosch
    Stinson, John
    Carrascosa, Jose Manuel
    DERMATOLOGY AND THERAPY, 2024, 14 (04) : 983 - 992
  • [25] Tralokinumab treatment substantially improves patient-reported outcomes in adolescents with moderate-to-severe atopic dermatitis at 16 weeks
    Soong, Weily
    Blauvelt, Andrew
    Wollenberg, Andreas
    Hong, H. Chih-ho
    Leflein, Jeffrey
    Bewley, Anthony
    Amoudruz, Petra
    Moerch, Marie Holst
    Soldbro, Lise
    Schneider, Shannon
    Simpson, Eric L.
    Paller, Amy
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E91 - E92
  • [26] Efficacy and safety of tralokinumab monotherapy in North American adult patients with moderate-to-severe atopic dermatitis: A subanalysis of the ECZTRA 2 trial
    Wiseman, Marni
    Armstrong, April W.
    Soung, Jennifer
    Albrecht, Lorne
    Lomaga, Mark
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB178 - AB178
  • [27] Efectiveness and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a 64-week follow-up study
    Lopez-Vinardell, L.
    Gras Martin, L.
    Garin Escriva, N.
    Riera Armengol, P.
    Serra Baldrich, E.
    Zurita Alonso, B.
    Mas Malagarriga, N.
    Conejo Marin, I.
    Masip Torne, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 279 - 279
  • [28] Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study
    Pezzolo, Elena
    Schena, Donatella
    Gambardella, Alessio
    Rossi, Mariateresa
    Barei, Francesca
    Pinton, Piergiacomo Calzavara
    Girolomoni, Giampiero
    Naldi, Luigi
    Ferrucci, Silvia Mariel
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (01) : E11 - E13
  • [29] Efficacy and safety of dupilumab in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A. S.
    Simpson, E. L.
    Siegfried, E. C.
    Cork, M. J.
    Wollenberg, A.
    Arkwright, P. D.
    Soong, W.
    Gonzalez, M. E.
    Schneider, L. C.
    Sidbury, R.
    Lockshin, B.
    Wang, Z.
    Mannent, L. P.
    Amin, N.
    Sun, Y.
    Laws, E.
    Akinlade, B.
    Kosloski, M. P.
    Dubost-Brama, A.
    O'Malley, J. T.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E173 - E173
  • [30] Efficacy and safety of dupilumab in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, Amy S.
    Cork, Michael J.
    Siegfried, Elaine C.
    Simpson, Eric L.
    Wollenberg, Andreas
    Gonzalez, Mercedes E.
    Sun, Yiping
    O'Malley, John T.
    Bansal, Ashish
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 12 - 12
12345